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Column chromatography was performed on urine, saliva, plasma, and sputum from patients with cystic fibrosis. One heterogenous peak with a molecular weight of approximately 200,000 was noted in all fluids examined and-was similar to the CEA peak obtained from colon tumors. Another peak appeared in the void column which corresponded to a molecular weight equal to or greater than 1 million. The latter peak was found in all fluids except plasma. The activity profiles of CEA activity of the physiologic fluids in normal patients and patients with cystic fibrosis were similar.
Speculation
The correlation of plasma CEA levels with the amount of sputum production in patients with C F may explain the similar elevation of Plasma-CEA in chronic bronchitis, pulmonary tuberculosis, pneumonia, and in smokers. In all of these subjects there is an increase in sputum production. It is also possible that CEA-active glycoproteins in the sputum and in the plasma of patients with cystic fibrosis are disease-associated abnormal glycoproteins. Further investigation may provide new leads to the pathogenesis of cystic fibrosis.
Cystic fibrosis is associated with abnormal mucus production. This abnormality is not only important in the pathogenesis of C F but has also been hypothesized as a basic defect in these children. Although numerous studies have been made to characterize the glycoproteins in this disease, the underlying biochemical defect has not been delineated. I n this paper we report our studies on the presence of carcinoembryonic antigenic-active molecules in patients with cystic fibrosis. I n 1965. Gold and Freedman (4) identified an oncofetal antigen in extracts of fetal gut and -bryonic antigen. The antigen was subsequently identified as a glycoprotein and was found to be localized in the glycocalyx of the plasma membranes of colonic tumor cells (3) . Several radioimmunoassays (8, 16) have been developed for determining the blood levels of CEA. Large scale collaborative studies (5, 7, 8) have established recently the blood CEA level as a useful adjunct in the diagnosis and management of the cancer patient. The presence of CEA in normal physiologic fluids and the suggestive evidence that CEA may be identical with an antigen in normal mucous cells (10-12) stimulated us to investigate the presence of this antigen in patients with cystic fibrosis.
CEA activity was measured in urine, saliva (9) , and plasma of cystic fibrosis and control children to see whether abnormal levels of this glycoprotein occur in patients with cystic fibrosis. Serial determinations of plasma CEA were made in some patients to determine whether levels varied with changes in clinical condition. Chromatography of CEA-active molecules in the saline extracts of urine, saliva, plasma, and sputum from patients with cystic fibrosis was performed for the purpose of characterization.
MATERIALS A N D METHODS
Samples of plasma, urine, and saliva were obtained from cystic fibrosis children and control children. Sputum samples were available only from the cystic fibrosis patients. All specimens were refrigerated immediately and the C E A levels were determined within 2 days. Salivary samples were obtained by expectoration of saliva. Onlv the viscous oortion of freshlv obtained soutum samples were used in order to minimize salivary contamination. CEA levels in plasma were determined by a zirconium phosphate gel radioimmunoassay. The same procedure was used to determine the CEA levels in the urine and saliva except that pretreatment of the sample with perchloric acid was omitted. Unlike plasma, no protein precipitates occurred after perchloric acid treatment of urine and saliva, and such treatment merely lowers CEA activity. Because of the high activity of C E A in urine and saliva, care was exercised to employ appropriate aliquots so that the results would fall within the range of the standard inhibition curve. These aliquots were always less than the 0.5-ml quantity used in the assay of CEA in plasma. The assay was also modified in that the samples of urine, saliva, and standard C E A were radioimmunoassayed under the same buffer condition (0.05 M ammonium acetate at pH 6.5). The procedures for Sepharose 6B column chromatography, creatinine, and protein determinations have all been described in a previous communication (18) . Cystic fibrosis was diagnosed on the basis of at least two determinations of elevated sweat chloride and a typical clinical course. The severity of the clinical involvement was established according to the scoring system proposed by Shwachman in which a score of 100 indicates a healthy individual, and scores of less than 50 indicate severe involvement (15) .
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RESULTS
CORRELATION OF PLASMA CEA WITH SEVERITY OF CYSTIC FIBROSIS
CEA levels in plasma, urine, and saliva from children with and without cystic fibrosis are shown in Table 1 . The plasma levels of C E A in cystic fibrosis children were found to be significantly higher than the reported upper range for normal subjects (2.5 ng/ml) and for our control patients of comparable age. The significance of the association between C F and elevated plasma C E A concentration is more apparent when plasma C E A is compared with the Scwachman score of the individual child. Values from 22 children are plotted in Figure 1 . The regression line was computed by the method of least square statistical analysis, ' Number of children is in parentheses. and the correlation coefficient was 0.87. The plasma CEA activity of four children with C F who had wide variations in the severity of clinical disease was monitored over a 10-month period to determine whether plasma CEA levels reflected changes in the severity of the disease. Changes in plasma C E A values and variation in severity of the clinical condition, as reflected in the Schwachman score, are depicted in Figure 2 . In each individual, variations in plasma CEA values are associated with a similar change in the Schwachman score. The change in plasma values could be quite rapid; in one patient there was a decrease from 9 to 5 ng/ml of C E A in 4 days during a time when there was a rapid improvement in the clinical score. The concentration of CEA active molecules in urine and saliva was much higher than in blood (Table I) , but there was no correlation between plasma and urinary or plasma and salivary levels of CEA. Furthermore, no difference was found between C F and control patients in salivary or urinary levels of CEA.
It was observed during the follow-up studies noted above that the plasma C E A levels not only correlated with the severity of the disease as reflected in the Shwachman score but was also correlated with the severity of the lung disease, especially with the profuseness of rales and rhonchi and the amount of sputum production.
This Dart of the study was designed to determine whether the CEA-active molecules detected in the body fluids of C F patients differed from CEA derived from colon tumors or CEA-active molecules of the normal physiologic fluids. Samples containing CEA activity were subjected to chromatography on a Sepharose 6B column. For urine and saliva, the clear saline extract of pooled specimens was employed. For plasma, perchloric acid treatment was necessary to remove the majority of the plasma pro- teins before the plasma could be concentrated prior to column application. The results are shown in Figure 3 . The CEA activity profiles show no apparent difference from that of normal physiologic fluids (I 7). Repeated studies consistently showed two groups of C E A activity peaks in the saliva and urine extracts. Group I molecules appeared at the void volume of the column which corresponded to a molecular size equal to or larger than 1 million, and a second heterogenous group of molecules (group 11) appeared later with molecular weights of approximately 200,000. In plasma there was only a single C E A activity peak, the size of the molecule being similar to that of colon tumor-CEA, approximately 200,000.
The sputum from patients with C F was mixed with an equal volume of cold saline and stirred gently at 4' for approximately I hr until it was dispersed into a homogeneous fluid.
This fluid was then centrifuged at 27,000 x g for 30 min, and the supernatant fraction was used for CEA measurement and column chromatography. Very high CEA activity and specific activity (373 ng C E A / m g protein) were found in sputum saline extracts. The inhibition curve of sputum CEA was parallel with that of the C E A standard. Repeated extractions indicated that the majority of the C E A activity (75%) was present in the first extract with very little being solubilized after the third extraction ( Table 2 ). The profile of C E A activity after column chromatography is plotted in Figure 4 . Similar to what we have noted in urine and saliva there were again group I and group II CEA activity peaks with molecular weights in the neighborhood of I million and 200,000, respectively.
DISCUSSION
It is now accepted that CEA is neither tumor specific nor of entodermal origin and that the level of plasma CEA may be elevated in various neoplastic diseases as well as in diseases of nonmalignant origin (5, 7). The plasma CEA test has been found to be of value in monitoring the effectiveness of therapy and the 4 . Column chromatography of saliva extracts of sputum from children with cystic fibrosis with or without treatment with 0.6 M perchloric acid. The condition is the same as we described in Figure 3 . Before acid treatment both samples contained the same amount of carcinoembryonic antigen (CEA) activity. The column and the buffer were the same as described in the legend of Figure 3 . development of tumor recurrences ( 5 , 8) . However, it was noticed by Hansen et al. (5) that except for pancreatic and colorectal carcinoma, titers above 20 ng/ml are rare and are usually associated with the presence of metastatic disease. Our results show that patients with CF, a disease that is not associated with malignancy, can have plasma C E A levels as high as 40 ng/ml. The mechanism whereby plasma C E A becomes elevated in cystic fibrosis is unknown at the present time. However, we have found that the plasma C E A levels in patients with C F are correlated with the severity of the disease. The correlation of the plasma C E A levels with Schwachman score in individuals seems best correlated with the severity of the lung disease and the amount of sputum production in the patient. It is possible that the mechanism for the increase in plasma CEA in cystic fibrosis patients may be similar to the increase noted in chronic bronchitis, pulmonary tuberculosis, pneumonia, and in smokers (5) . In all of these conditions there is an increase in mucus production in the lungs, and the CEAactive molecules in the sputum may be transferred into the plasma. The extremely high concentration and specific activity of CEAactive molecules that we have noted in the sputum of C F patients would tend to support this idea. The sputum from C F patients contains the highest concentration of C E A of any body fluid we have examined (17) and is similar to that detected in extracts of colon tumors. The slope of the C E A inhibition curve of sputum indicates sputum C E A has the same high affinity toward anti-CEA antiserum as colon tumor CEA.
Unlike blood plasma, most other human physiologic fluids (17) consistently showed two groups of CEA-active molecules after Sepharose 6B column chromatography. Similar patterns were observed in sputum from patients with cystic fibrosis. Only a single CEA-active peak with molecular weight close to 200,000 was detected in the plasma. If plasma CEA of cystic fibrosis patients is indeed derived from sputum it would be interesting to find out why only the smaller C E A molecules (mol wt approximately 200,000) and not the larger species (mol wt approximately 1,000,000) appeared in the blood. In our previous study of urinary CEA, we failed to demonstrate that the group I CEA-active molecules are an aggregate of the group I I molecules. We are not yet certain whether the conversion of the large molecule to the smaller molecule occurs before it enters the blood. It is also possible that the size of the large molecule simple prevents its entrance into the vascular compartment.
The techniques used in the present study differentiate the CEA-active molecules only according to differences in size. It will be important to determine whether other differences may be present between CEA-active molecules from sputum and plasma of cystic fibrosis patients and those derived from colon tumor.
In addition to CEA-active molecules, which are glycoproteins, many other abnormal proteins and glycoproteins have been noted to be associated with cystic fibrosis. Among these are cystic fibrosis ciliary inhibitory factor found in serum and saliva (18) , calcium binding protein in the submaxillary saliva (1, 2) , and glycoproteins in the sputum of these patients (6, 13, 14) . Comparison between CEA-active molecule and these other glycoproteins in cystic fibrosis deserves further investigation. In the present study we could show only an abnormal increase of CEA-active molecule in the blood but could not demonstrate an abnormal increase in the saliva of cystic fibrosis patients as has been done with the other abnormal glycoproteins.
SUMMARY
Elevated levels of plasma C E A were found in patients with cystic fibrosis. The elevations were well correlated with the Shwachman scores of the patients. Parallel changes of the levels of plasma CEA and clinical conditions of four patients were also observed in the follow-up studies. Close clinical examination indicated that the elevated plasma C E A of cystic fibrosis patients may be derived from sputum which is produced in abnormal amounts. This hypothesis is further supported by the very high 238 KIM ET A L .
content and the chromatographic profile of the CEA activity of sputum from patients with cystic fibrosis.
